Buflomedil hydrochloride

SKU: orb1310728

Description

Buflomedil hydrochloride

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 35543-24-9
• MW: 343.85
• Purity: 99.91%
• Formula: C₁₇H₂₆ClNO₄
• SMILES: Cl.COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1
• Target: Adrenergic Receptor,Others

Bioactivity

• Target IC50:
  α1A-adrenoceptor (rat):4.06 μM (Ki)|α1B-adrenoceptor:6.84 μM (Ki)
• In Vitro:
  Buflomedil enhances intracellular cAMP levels in human keratinocytes, either secondary to adenyl-cyclase stimulation (BC) or phosphodiesterase inhibition (PTX). Buflomedil diminishes release of TPA-induced TNF-alpha and IL-8 in keratinocytes; in the case of IL-8, this inhibition may occur to transcriptional level. At the micromolar level, Buflomedil notably inhibits epinephrine-induced aggregation. Buflomedil leads to a weak inhibition of collagen- and ADP-induced aggregation. Buflomedil inhibits grainy secretion and the interaction of fibrinogen with its receptor on platelet. the capillary perfusion is improved by Buflomedil hypochloride in such related situations, evoking a possible effect upon neutrophils. Buflomedil Completely inhibits adhesion of histamine related neutrophil (flow system) and partially inhibits adhesion after IL-1-4 hours (flow and stable systems). Buflomedil lowers the hypoxia-induced neutrophil adhesion and expression of P-selectin at the surface of endothelial cells.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Buflomedil, Buflomedil HCl, Buflomedil hydrochloride, Buflomedil Hydrochloride, Adrenergic Receptor, AdrenergicReceptor, inhibit, Loftyl, Inhibitor, Fonzylane, α-adrenergic receptor

Compound Identifiers

PubChem CID

6420013